Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) has signed a letter of intent with Constance Therapeutics of San Francisco for the clinical development and commercialization in Canada of its signature medicinal cannabis extract products.Read More
Tetra Bio-Pharma (OTCQB:TBPMF; CSE:TBP) and the New Brunswick Health Research Foundation are investing $500,000 each over five years to establish a health research chair in cannabis at the University of New Brunswick.Read More
Roth Capital Partners launched coverage of Sorrento Therapeutics (NASDAQ:SRNE) with a “buy” rating and $15 price target. The stock closed at $7.74 on Friday.
Sorrento has a proprietary fully human antibody library platform used to screen and identify highly specific monoclonal antibodies that can be used as therapeutic candidates. The company also has established an integrated network of subsidiaries and collaborations, with the idea to develop an extensive range of product candidates.Read More
Leerink Partners has initiated coverage of Depomed (NASDAQ:DEPO) with an “outperform” rating and $21 price target. The stock closed at $14.62 on Wednesday.
“Depomed’s Nucynta for chronic pain provides a differentiated and durable growth asset, and we expect shares to appreciate over the next 12 months, driven by a Nucynta patent settlement and continued acceleration of script trends,” writes analyst Jason Gerberry.Read More
William Blair & Co. has initiated coverage of Collegium Pharmaceutical (NASDAQ:COLL) with an “outperform” rating and price target of $35. The stock closed at $19.25 on Thursday.
Collegium’s lead product, Xtampza ER, an extended-release oxycodone-based product with abuse-deterrent technology (ADT), has received tentative approval from the FDA for the treatment of chronic pain that requires around-the-clock opioid analgesia for an extended period.Read More